drugset / Trial / NCT06614985
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
RandomizedSequentialOpen-labelTreatment
Summary
This is a multiple-center, prospective, open-label, positive drug controlled, randomized, clinical study to evaluate the safety and efficacy of Telitacicept in the treatment of primary membranous nephropathy.
Timeline
- Start
- 2024-10-20
- Primary completion
- 2026-10-01
- Completion
- 2027-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 0.4 g | Intravenous |
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Background | Prednisone | Other / unclassified | — | Oral |